Skip to content

A Dual-Action CXCR4-Targeted Peptide−Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer

Aug 2026 · Molecular Pharmaceutics · 0 citations · 50 references

TL;DR

P12-GEM possesses dual functions of CXCR4 antagonism and tumor cell killing, contributing to reversal of the immunosuppressive microenvironment and alleviation of myelotoxicity.

Abstract

Gemcitabine (GEM) is a first-line therapeutic option for pancreatic cancer; however, it has low efficacy due to rapidly developed drug resistance and severe dose-limiting myelosuppression. To enhance its therapeutic effect, this study developed a novel peptide−drug conjugate using a CXCR4 antagonistic peptide as the targeting head and gemcitabine as the drug payload, based on the characteristics of pancreatic tumor cells highly expressing CXCR4 that mediates immunosuppression and tumor progression through interaction with its specific ligand CXCL12. The therapeutic effect of the conjugate (P12-GEM) was investigated using pancreatic ductal adenocarcinoma cell lines and an orthotopic pancreatic cancer mouse model. Its myelosuppressive effect was assessed from the perspective of hematological toxicity profiles. The results showed that P12-GEM maintained a cell-killing capability comparable to that of GEM while effectively inhibiting the phosphorylation of Erk and P38, thereby reducing CXCL12-mediated tumor cell migration and adhesion to stromal cells. In a tumor-bearing mouse model, P12-GEM demonstrated superior antitumor efficacy compared to GEM and significantly extended animal survival. Moreover, P12-GEM reduced the proportion of tumor-associated macrophages and increased the infiltration of CD8+ T cells in the tumor microenvironment without reducing platelet and white blood cell counts in the peripheral blood. In summary, P12-GEM possesses dual functions of CXCR4 antagonism and tumor cell killing, contributing to reversal of the immunosuppressive microenvironment and alleviation of myelotoxicity.

View source

Similar papers

Sep 2026

Abstract B075: Harnessing Tumor-Penetrating Peptides to Modulate the Pancreatic Tumor Immune Microenvironment

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...

Shawn A. Abeynaike, In Hwan Park, Ashley Martinez et al. · 0 citations
Open access Sep 2026

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.

X. Che, Un-Jung Yun, Junsub Lee et al. · 0 citations
Review Open access Sep 2026

Antibody–drug conjugates in gastric cancer: from targeted cytotoxicity to immune modulation

Next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer, and integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations.

Hong-Hua Su, Chun-Yin Yang, Jia-Yun Ge · 0 citations
Open access Sep 2026

Targeted Cepharanthine-Mediated Dual-Pathway Inhibition Sensitizes Pancreatic Cancer to Gemcitabine

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, and gemcitabine (GEM) resistance is a major contributor to its poor clinical outcomes, generating an urgent need for novel therapeutic strategies targeting tumor proliferation and tumor-cell-intrinsic malignant signaling. This study aimed to investi...

Tong-Shan Zhu, Shu-Mei Zhang, Meng-Xin Hao et al. · 0 citations
Open access Oct 2026

Antitumor efficacy of PD-1 blocking antibody is enhanced through liposomal delivery and myeloid immune modulation.

Systemic monoclonal antibody therapy against the PD-1 immune checkpoint (anti-PD1) is efficacious in less than 40% of patients with solid tumors. Beyond T-cells, PD-1 is expressed on myeloid populations such as monocytes, dendritic cells, myeloid progenitors, and tumor-associated macrophages (TAMs) that also have a pro...

Md. Rakibul Islam, J. Patel, P. Back et al. · 0 citations
Sep 2026

CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.

It is found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth, and the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway.

Zuofei Chi, Nan-Nan Xu, Ying Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.